348 related articles for article (PubMed ID: 31616143)
1. Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment.
Albash R; El-Nabarawi MA; Refai H; Abdelbary AA
Int J Nanomedicine; 2019; 14():6555-6574. PubMed ID: 31616143
[TBL] [Abstract][Full Text] [Related]
2. Use of transethosomes for enhancing the transdermal delivery of olmesartan medoxomil: in vitro, ex vivo, and in vivo evaluation.
Albash R; Abdelbary AA; Refai H; El-Nabarawi MA
Int J Nanomedicine; 2019; 14():1953-1968. PubMed ID: 30936696
[TBL] [Abstract][Full Text] [Related]
3. Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment.
Kamran M; Ahad A; Aqil M; Imam SS; Sultana Y; Ali A
Int J Pharm; 2016 May; 505(1-2):147-58. PubMed ID: 27005906
[TBL] [Abstract][Full Text] [Related]
4. "Employment of PEGylated ultra-deformable transferosomes for transdermal delivery of tapentadol with boosted bioavailability and analgesic activity in post-surgical pain".
Deng P; Athary Abdulhaleem M F; Masoud RE; Alamoudi WM; Zakaria MY
Int J Pharm; 2022 Nov; 628():122274. PubMed ID: 36228884
[TBL] [Abstract][Full Text] [Related]
5. Fabrication of novel elastosomes for boosting the transdermal delivery of diacerein: statistical optimization, ex-vivo permeation, in-vivo skin deposition and pharmacokinetic assessment compared to oral formulation.
Aziz DE; Abdelbary AA; Elassasy AI
Drug Deliv; 2018 Nov; 25(1):815-826. PubMed ID: 29557244
[TBL] [Abstract][Full Text] [Related]
6. Investigating the potential of employing bilosomes as a novel vesicular carrier for transdermal delivery of tenoxicam.
Al-Mahallawi AM; Abdelbary AA; Aburahma MH
Int J Pharm; 2015 May; 485(1-2):329-40. PubMed ID: 25796122
[TBL] [Abstract][Full Text] [Related]
7. Fabrication of Highly Deformable Bilosomes for Enhancing the Topical Delivery of Terconazole: In Vitro Characterization, Microbiological Evaluation, and In Vivo Skin Deposition Study.
Mosallam S; Sheta NM; Elshafeey AH; Abdelbary AA
AAPS PharmSciTech; 2021 Feb; 22(2):74. PubMed ID: 33586022
[TBL] [Abstract][Full Text] [Related]
8. Transdermal Delivery of Ondansetron Hydrochloride via Bilosomal Systems: In Vitro, Ex Vivo, and In Vivo Characterization Studies.
Ammar HO; Mohamed MI; Tadros MI; Fouly AA
AAPS PharmSciTech; 2018 Jul; 19(5):2276-2287. PubMed ID: 29845503
[TBL] [Abstract][Full Text] [Related]
9. Bilosomes as Promising Nanovesicular Carriers for Improved Transdermal Delivery: Construction, in vitro Optimization, ex vivo Permeation and in vivo Evaluation.
Ahmed S; Kassem MA; Sayed S
Int J Nanomedicine; 2020; 15():9783-9798. PubMed ID: 33324052
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of bilosomes as nanocarriers for transdermal delivery of tizanidine hydrochloride: in vitro and ex vivo optimization.
Khalil RM; Abdelbary A; Kocova El-Arini S; Basha M; El-Hashemy HA
J Liposome Res; 2019 Jun; 29(2):171-182. PubMed ID: 30221568
[TBL] [Abstract][Full Text] [Related]
11. In Vitro and In Vivo Evaluation of Olmesartan Medoxomil Microcrysta ls and Nanocrystals: Preparation, Characterization, and Pharmacokinet ic Comparison in Beagle Dogs.
Chai R; Gao H; Ma Z; Guo M; Fu Q; Liu H; He Z
Curr Drug Deliv; 2019; 16(6):500-510. PubMed ID: 31244438
[TBL] [Abstract][Full Text] [Related]
12. Chitosan nanoparticles for intranasal delivery of olmesartan medoxomil: Pharmacokinetic and pharmacodynamic perspectives.
Hassan RH; Gad HA; El-Din SB; Shaker DS; Ishak RAH
Int J Pharm; 2022 Nov; 628():122278. PubMed ID: 36243325
[TBL] [Abstract][Full Text] [Related]
13. Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability.
Kaithwas V; Dora CP; Kushwah V; Jain S
Colloids Surf B Biointerfaces; 2017 Jun; 154():10-20. PubMed ID: 28284054
[TBL] [Abstract][Full Text] [Related]
14. Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation.
Nooli M; Chella N; Kulhari H; Shastri NR; Sistla R
Drug Dev Ind Pharm; 2017 Apr; 43(4):611-617. PubMed ID: 28005442
[TBL] [Abstract][Full Text] [Related]
15. Formulation, optimization, and in vitro-in vivo evaluation of olmesartan medoxomil nanocrystals.
Jain S; Patel K; Arora S; Reddy VA; Dora CP
Drug Deliv Transl Res; 2017 Apr; 7(2):292-303. PubMed ID: 28116656
[TBL] [Abstract][Full Text] [Related]
16. Brij® integrated bilosomes for improving the transdermal delivery of niflumic acid for effective treatment of osteoarthritis: In vitro characterization, ex vivo permeability assessment, and in vivo study.
Abdelbari MA; El-Gazar AA; Abdelbary AA; Elshafeey AH; Mosallam S
Int J Pharm; 2023 Jun; 640():123024. PubMed ID: 37156309
[TBL] [Abstract][Full Text] [Related]
17. Investigating superiority of novel bilosomes over niosomes in the transdermal delivery of diacerein: in vitro characterization, ex vivo permeation and in vivo skin deposition study.
Aziz DE; Abdelbary AA; Elassasy AI
J Liposome Res; 2019 Mar; 29(1):73-85. PubMed ID: 29355060
[TBL] [Abstract][Full Text] [Related]
18. Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers.
Alsofany JM; Hamza MY; Abdelbary AA
AAPS PharmSciTech; 2018 Jul; 19(5):2118-2132. PubMed ID: 29700766
[TBL] [Abstract][Full Text] [Related]
19. Utilization of PEGylated cerosomes for effective topical delivery of fenticonazole nitrate:
Albash R; Yousry C; Al-Mahallawi AM; Alaa-Eldin AA
Drug Deliv; 2021 Dec; 28(1):1-9. PubMed ID: 33322971
[TBL] [Abstract][Full Text] [Related]
20. Response Surface Optimization of Ultra-Elastic Nanovesicles Loaded with Deflazacort Tailored for Transdermal Delivery: Accentuated Bioavailability and Anti-Inflammatory Efficacy.
Ali AA; Hassan AH; Eissa EM; Aboud HM
Int J Nanomedicine; 2021; 16():591-607. PubMed ID: 33531803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
